Spesolimab-sbzo (Spevigo)

Provider Order Form rev. 09/19/2024

PATIENT INFORMATION

Referral Status: ☐ New Referral ☐ Updated Order ☐ Order Renewal

Patient Name: DOB: Patient Phone:

Patient Address: Patient Email:

Allergies: ☐ NKDA Weight (lbs/kg): Height (in/cm):

Sex: ☐ M / ☐ F Date of Last Infusion: Next Due Date: Preferred Location:

DIAGNOSIS *(Please provide ICD-10 code in space provided)*

Generalized Pustular Psoriasis:

Other: Description:

THERAPY ADMINISTRATION & DOSING

For Treatment of GPP Flare

☐ Administer Spevigo 900mg IV one time over 90 mins in 100ml NS

☐ May repeat dose one additional time in 1 week if flare persist

For Treatment of GPP When Not Experiencing a Flare

☐ Induction: Administer Spevigo 600mg (as four 150mg injections) SQ in the abdomen or thigh on week 0

☐ Maintenance: Administer Spevigo 300mg (as two 150mg injections) SQ in the abdomen or thigh every 4 weeks

ADDITIONAL ORDERS

PRE-MEDICATION ORDERS

☐ Tylenol ☐ 500mg / ☐ 650mg PO

☐ Loratadine 10mg PO

☐ Pepcid 20mg ☐ PO / ☐ IVP

☐ Benadryl ☐ 25mg / ☐ 50mg ☐ PO / ☐ IVP

☐ Solumedrol ☐ 40mg / ☐ 125mg IVP

☐ Other: _____

NURSING

☑ Hold infusion and notify provider for:

- Signs or symptoms of illness or active infection
- Planned/recent surgical procedures or recent live vaccines.

☑ Infusion must be complete within 180 minutes.

☑ Provide nursing care per Nursing Procedure, including Hypersensitivity Reaction Management Protocol and post-procedure observation

PROVIDER INFORMATION

Preferred Contact Name: Preferred Contact Email:

Ordering Provider: Provider NPI:

Referring Practice Name: Phone: Fax:

Practice Address: City: State: Zip Code:

REQUIRED DOCUMENTATION CHECKLIST *(Additional documentation required for processing and insurance approval)*

Required Documentation: Patient demos, copy of front and back of primary and secondary insurance, 2 most recent OVN including treatment failures or contraindications, BSA affected

Provider Name *(print)* **Provider Signature** **Date**

Order valid for one year unless otherwise indicated. IV solutions/diluents may be substituted as allowed per manufacturer's instructions as necessitated by product availability.